D8-MMAD


Catalog No. Size PriceQuantity
M12177-2 2mg solid $2,090
M12177-10 10mg solid $8,360

Description

D8-MMAD is a deuterated form of MMAD, which is a microtubule disrupting agent.

Product information

Molecular Weight: 779.11

Formula: C41H66N6O6S

Synonym:

Demethyldolastatin 10 D8

Monomethylauristatin D D8

Monomethyl Dolastatin 10 D8

Chemical Name: (2S)-N-[(3R, 4S, 5S)-3-methoxy-1-[(2S)-2-[(1R, 2R)-1-methoxy-2-methyl-2-{[(1S)-2-phenyl-1-(1, 3-thiazol-2-yl)ethyl]carbamoyl}ethyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-3-(H)methyl-N-methyl-2-[(2S)-3-methyl-2-(methylamino)butanamido](H)butanamide

Smiles: [2H]C([C@]([2H])(NC(=O)[C@@H](NC)C(C)C)C(=O)N(C)[C@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](CC1C=CC=CC=1)C1=NC=CS1)OC)[C@@H](C)CC)(C([2H])([2H])[2H])C([2H])([2H])[2H]

InChiKey: BLUGYPPOFIHFJS-JVNODLFUSA-N

InChi: InChI=1S/C41H66N6O6S/c1-12-27(6)36(46(9)41(51)35(26(4)5)45-39(50)34(42-8)25(2)3)32(52-10)24-33(48)47-21-16-19-31(47)37(53-11)28(7)38(49)44-30(40-43-20-22-54-40)23-29-17-14-13-15-18-29/h13-15,17-18,20,22,25-28,30-32,34-37,42H,12,16,19,21,23-24H2,1-11H3,(H,44,49)(H,45,50)/t27-,28+,30-,31-,32+,34-,35-,36-,37+/m0/s1/i4D3,5D3,26D,35D

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : ≥ 100 mg/mL (128.35 mM)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥360 days if stored properly.

Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

MMAD (Monomethyl Dolastatin 10) is coupled through a stable oxime-ligation process to yield several near-homogenous antibody-drug conjugates (ADCs) with a drug-to-antibody ratio of ~2.0. The resulting conjugates demonstrate good pharmacokinetic properties, potent in vitro cytotoxic activity against HER2+ cancer cells. When compared with ADCs prepared by cysteine alkylation following native interchain disulfide reduction, site-specific unnatural-amino-acid-based ADCs are shown to have increased in vitro cytotoxicity.

In Vivo:

The resulting antibody-drug conjugates (ADCs) demonstrate complete tumour regression in rodents. They also have an improved toxicology profile in rats.

References:

  1. Chudasama V, et al. Recent advances in the construction of antibody-drug conjugates. Nat Chem. 2016 Feb;8(2):114-9.

Products are for research use only. Not for human use.

Payment & Security

American Express Diners Club Discover JCB Mastercard PayPal Venmo Visa

Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.

Estimate shipping

You may also like

Recently viewed